Vitamin e neuroprotection for cisplatin neuropathy: A randomized, placebo-controlled trial

Neurology

Volumn 74, Issue 9, 2010, Pages 762-766

  Pace, A ^a   Giannarelli, D ^a   Galie E ^a   Savarese, A ^a   Carpano, S ^a   Della Giulia, M ^a   Pozzi, A ^a   Silvani, A ^b   Gaviani, P ^b   Scaioli, V ^b   Jandolo, B ^a   Bove, L ^a   Cognetti, F ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; CISPLATIN; PLACEBO; RIGENTEX; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; ELECTROPHYSIOLOGY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROPATHY; NEUROPHYSIOLOGY; NEUROPROTECTION; NEUROTOXICITY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION;

EID: 77649243226     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181d5279e     Document Type: Article

References (26)

1. Hamers FPT, Gispen WH, Neijt JP. Neurotoxic side effects of cisplatin. Eur J Cancer 1991;27:372-376.
2. Alberts DS, Noel JK. Cisplatin-associated neurotoxicity: can it be prevented? Anticancer Drugs 1995;6:369-383.
3. Cavaletti G, Tredici G, Marmiroli P. Morphometric study of the sensory neuron and peripheral nerve changes induced by chronic cisplatin (CDDP) administration in rats. Acta Neuropathol 1992;84:364-371.
4. Krarup-Hansen A, Helweg-Larsen S, Schmalbruch H, Rorth M, Krarup C. Neuronal involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies. Brain 2007;130:1076-1088.
5. McDonald ES, Randon KR, Knight A, Windebank AJ. Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for neurotoxicity. Neurobiol Dis 2005;18:305-313.
6. Krarup-Hansen A, Rietz B, Krarup C, et al. Histology and platinum content of sensory ganglia and sural nerves in patients treated with cisplatin and carboplatin: an autopsy study. Neuropathol Appl Neurobiol 1999;25:29-40.
7. Vasigara SW, Subramaniam S, Subramaniam S, et al. Levels of antioxidants in haemolysates from breast cancer patients after chemo-and radiotherapy. Med Sci Res 1996; 24:195-197.
8. Weijl NI, Hopman GD, Wipkink-Bakker A, et al. Cispla-tin combination chemotherapy induces a fall in plasma antioxidants of cancer patients. Ann Oncol 1998;9:1331-1337.
9. Moss RW. Should patients undergoing chemotherapy and radiotherapy be prescribed antioxidants? Integrative Cancer Therapies 2006;5:63-82.
10. Bove L, Picardo M, Maresca V, et al. A pilot study on the relationship between cisplatin neuropathy and vitamin E. J Exp Clin Cancer Res 2001;20:277-280.
11. Argyriou AA, Chroni E, Koutras A, et al. Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial. Neurology 2005;64:26-31. (Pubitemid 40082932)
12. Block KI, Koch AC, Mead MN, et al. Impact of antioxi-dant supplementation on chemotherapeutic toxicity: a systematic review of the evidence from randomized controlled trials. Int J Cancer 2008;123:1227-1239.
13. Rybak LP, Husain K, Morris C, et al. Effect of protective agents against cisplatin ototoxicity. Am J Otol 2000;21: 513-520.
14. Kalkanis JG, Whitworth C, Rybak LP. Vitamin e reduces cisplatin ototoxicity. Laryngoscope 2004;114:538-542.
15. Traber MG, Sokol RJ, Ringel SP, et al. Lack of tocopherol in peripheral nerves of vitamin E deficient patients with peripheral neuropathy. N Engl J Med 1987;262-265.
16. Muller DPR, Lloid JK, Wolff OH. Vitamin E and neurological function. Lancet 1983;29:225-228.
17. Pace A, Savarese A, Picardo M, et al. Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. J Clin Oncol 2003;21:927-931.
18. Albers J, Chaudhry V, Cavaletti G, Donehower R. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev 2007;1: CD005228.
19. Cavaletti G, Bogliun G, Marzorati L, et al. Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale. Neurology 2003;61:1297-1300.
20. Pace A, Bove L, Aloe A, et al. Paclitaxel neurotoxicity: clinical and neurophysiological study in 23 patients. Ital J Neurol Sci 1996;18:73-79.
21. Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C. Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer 2008;44:1507-1515.
22. Peltier AC, Russell JW. Recent advances in drug-induced neuropathies. Curr Opin Neurol 2002;15:633-638.
23. Windebank AJ, Smith AG, Russel JW. The effect of nerve growth factor, ciliary neurotrophic factor, and ACTH analogs on cisplatin neurotoxicity in vitro. Neurology 1994; 44:488-494.
24. Goss-Sampson MA, MacEvilly CJ, Muller DPR. Longitudinal studies of the neurobiology of vitamin E and other antioxidant systems, and neurological function in the vitamin E deficient rat. J Neurol Sci 1988;87: 25-35.
25. Sen CK, Khanna S, Roy S. Tocotrienol, the natural vitamin E to defend the nervous system? Ann NY Acad Sci 2004;1031:127-142.
26. Leonetti C, Biroccio A, Gabellini C, et al. Alpha-tocopherol protects against cisplatin-induced toxicity without interfering with antitumor efficacy. Int J Cancer 2003; 104:243-250.